Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Sep 15, 2022 2:10pm
134 Views
Post# 34964974

RE:RE:RE:More of the same

RE:RE:RE:More of the sameThe situation is clear, volume is very low, even on the day of the last PR on article on the effect of TH1902 on cancer stem cells. Actual shareholders are not willing to sell at the actual price, and potential buyers wait for confirmation that TH1902 is a legit drug candidate, i.e., clear proof of concept. That being said, the company is not shy to talk about cancer while they know what is going on in the phase Ib that is now many months in. So it's a waiting game.



barsax wrote: "Someone from TD dumped $100,000 worth of stock "

That is 100% true.  At 11:21 EDT someone dumped >$100,000USD worth of stock.

I have to say, though, since the beginning of the week it looks to me like someone is establishing a sizeable position in the stock.  Its trading well, despite the constant chorus of complaints from the same cast of characters 


<< Previous
Bullboard Posts
Next >>